Status and phase
Conditions
Treatments
About
A 2 parts Phase II study to investigate the effect on central macular thickness of treatment with MG-O-1002 eye drops in participants aged over 45 with neovascular age-related macular degeneration (nAMD)
Full description
Neovascular Age-related Macular Degeneration (nAMD) is a serious eye disease and a leading cause of irreversible blindness primarily in the older population. Current treatment with anti-vascular endothelial growth factor (VEGF), while effective, requires intravitreal injection meaning administration that needs to be performed by a specialist ophthalmologist and carries procedural risks. MG-O-1002 can be administered as a topical eye drop providing a potentially safer option that can be self-administered increasing accessibility. This study will evaluate the efficacy and safety of topical ocular use of MG-O-1002 in participants with nAMD.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Part 1:
Part 2:
Exclusion criteria
Part 1:
Part 2:
Primary purpose
Allocation
Interventional model
Masking
36 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
William Chen; Samjay Lin
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal